Live Feeds
● TRACKER Updated 6d ago · 7 sources tracked

Novartis pelacarsen Lp(a) trial fails, raising doubts for Amgen, Lilly

Novartis announced that a large clinical trial for its heart drug pelacarsen failed to meet expectations. The drug was intended to prevent heart attacks by targeting Lp(a), but the results have shocked cardiologists. This failure creates uncertainty for other companies in the multibillion-dollar race to develop Lp(a) therapies, specifically Amgen and Eli Lilly. The news has contributed to a volatile week for Novartis and triggered a significant stock decline for Amgen.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (8)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Novartis announced that a large clinical trial for pelacarsen failed.
  • ✓ The failure of the pelacarsen trial has raised doubts regarding Lp(a) drug efforts by Amgen and Eli Lilly.
  • ✓ Cardiologists expected the drug to prevent heart attacks.
🛡️ Source Corroboration: 7 independent reporting domains (90% confidence) ⏱ Read time: ~2 min

What changed

Novartis reported the failure of the pelacarsen clinical trial, causing market losses and casting doubt on competing Lp(a) programs.

Live updates

  1. Novartis Pelacarsen Trial Failure Impacts Lp(a) Drug Market

    Novartis announced that a large clinical trial for its heart drug pelacarsen failed to meet expectations. The drug was intended to prevent heart attacks by targeting Lp(a), but the results have shocked cardiologists. This failure creates uncertainty for other companies in the multibillion-dollar race to develop Lp(a) therapies, specifically Amgen and Eli Lilly. The news has contributed to a volatile week for Novartis and triggered a significant stock decline for Amgen.

    Why it matters

    Lp(a) is a type of cholesterol that clinicians hoped would be a new target for reducing cardiovascular risk. Pelacarsen was positioned as a primary weapon against heart attacks. The failure of this specific mechanism puts the viability of the entire Lp(a) drug field in question.

    What is confirmed

    • Novartis announced that a large clinical trial for pelacarsen failed.
    • The failure of the pelacarsen trial has raised doubts regarding Lp(a) drug efforts by Amgen and Eli Lilly.
    • Cardiologists expected the drug to prevent heart attacks.

    Still unconfirmed

    • Novartis lost more than $40 billion in market value following three clinical failures in one week.
    • Amgen stock suffered its worst day in more than two decades.

    What to watch next

    • Clinical trial results from Amgen or Eli Lilly targeting Lp(a)
    • Further data release from Novartis regarding the specific causes of the pelacarsen failure
    Sources used for this update (7)
    1. The New York Times — Another Heart Drug Fails, Shocking Cardiologists
    2. CNBC — Cholesterol drug setback casts doubt over multibillion-dollar race
    3. Barron's — One Stock Is Weighing Heavily on the Dow
    4. WSJ — Amgen Stock Suffers Worst Day in More Than Two Decades
    5. Yahoo Finance — Novartis pelacarsen Lp(a) trial fails, raising doubts for Amgen, Lilly
    6. finance.biggo.com — Stephen Anson: Novartis's Pelacarsen Failure Puts the Entire Lp(a) Drug Field on Trial
    7. medicalxpress.com — Cardiologists expected this new drug to prevent heart attacks—so why did it fail?
    confidence 90%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community